Stockscreener 앱 받기
3.065
10.65%
0.295
시간 외 거래:
3.06
-0.005
-0.16%
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Did You Suffer Losses in Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.
Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) Over Possible Securities Fraud - ACCESS Newswire
Levi & Korsinsky Launches Fraud Investigation on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders - ACCESS Newswire
(RCKT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $11.00 by Analysts at Canaccord Genuity Group - Defense World
RCKT ALERT: Ongoing Investigation Into Rocket Pharmaceuticals, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Rocket Pharmaceuticals (RCKT) Target Price Lowered by Canaccord Genuity | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Reduced Price Target Amid Cl - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Reduced Price Target Amid Clinical Hold Challenges | RCKT Stock News - GuruFocus
Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) Stock, Slashes PT - MSN
FY2025 Earnings Estimate for RCKT Issued By Chardan Capital - Defense World
Ongoing Investigation: Rocket Pharmaceuticals, Inc. (RCKT) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - PR Newswire
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Bank of America Corp DE - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Lowered to In-Line Rating by Evercore ISI - Defense World
Wedbush Brokers Increase Earnings Estimates for RCKT - Defense World
Leerink Partnrs Issues Optimistic Forecast for RCKT Earnings - Defense World
Securities Investigation: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) on Behalf of Investors - ACCESS Newswire
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Rocket Pharmaceuticals (RCKT) Faces Downgrade with New Price Tar - GuruFocus
RCKT ACTIVE INVESTIGATION: Lost Money on Rocket Pharmaceuticals, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setba - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setback | RCKT Stock News - GuruFocus
Evercore ISI Downgrades Rocket Pharmaceuticals to In Line From Outperform, $5 Price Target - marketscreener.com
Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) to In Line, 'removing from the SMID Core List' - StreetInsider
Jane Street Group LLC Has $508,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Millennium Management LLC Sells 865,586 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to “Hold” at Leerink Partnrs - Defense World
Equities Analysts Issue Forecasts for RCKT Q2 Earnings - Defense World
Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Rocket Pharmaceuticals (NASDAQ:RCKT) Given Hold Rating at Jefferies Financial Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Downgraded to “Sell” Rating by The Goldman Sachs Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to Sell at The Goldman Sachs Group - Defense World
RCKT ALERT: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. for Possible Securities Fraud Violations - ACCESS Newswire
Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies - MSN
Rocket Pharmaceuticals’ (RCKT) “Hold” Rating Reaffirmed at Jefferies Financial Group - Defense World
Rocket Pharmaceuticals’ (RCKT) “Market Perform” Rating Reaffirmed at Leerink Partners - Defense World
William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback - MSN
JPMorgan Downgrades Rocket Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $7 From $44 - marketscreener.com
The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move. - AOL.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Given New $19.00 Price Target at Scotiabank - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $9.00 at Bank of America - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Receives “Hold” Rating from Jefferies Financial Group - Defense World
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow - Insider Monkey
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty - Benzinga
Rocket Pharmaceuticals (RCKT) Faces Downgrade After Clinical Hol - GuruFocus
Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact - Seeking Alpha
Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death - MSN
Rocket Pharmaceuticals (RCKT) Analyst Rating Update: May 2025 | - GuruFocus
Rocket Pharmaceuticals (RCKT) Price Target Lowered by Scotiabank - GuruFocus
Rocket Pharmaceuticals (RCKT) Sees Significant Analyst Downgrade - GuruFocus
Rocket Pharmaceuticals (RCKT) Sees Significant Analyst Downgrade | RCKT Stock News - GuruFocus
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Deutsche Bank AG - Defense World
RCKT Stock Tanks on Patient Death in Danon Disease Study - Yahoo Finance
Rocket Pharmaceuticals (RCKT) Faces Price Target Cut Amid Clinical Hold | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Receives Downgrade and Price Targe - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Downgrade Amid Clinical Tria - GuruFocus
Rocket Pharmaceuticals (RCKT) Receives Downgrade and Price Target Reduction | RCKT Stock News - GuruFocus
1.21%
1.51%
자본화:
|
볼륨(24시간):